Tirzepatide
SURMOUNT-1
Eli Lilly · Phase 3 · Recruiting · Enrollment 2539
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Arm 1: Tirzepatide 5 mg once weekly + lifestyle intervention | Obesity, no T2D | 5 mg | 72 | n/r | n/r |
| Arm 2: Tirzepatide 10 mg once weekly + lifestyle intervention | Obesity, no T2D | 10 mg | 72 | n/r | n/r |
| Arm 3: Tirzepatide 15 mg once weekly + lifestyle intervention | Obesity, no T2D | 15 mg | 72 | n/r | n/r |
| Arm 4: Placebo once weekly + lifestyle intervention | Obesity, no T2D | n/r | 72 | n/r | n/r |